Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRN-001-03
- Development stage
- Preclinical
- Lead developer
- Proniras
- Modality
- Small Molecules
01
Overview
PRN-001-03 is a small molecule drug candidate being developed by Proniras for the treatment of alcohol withdrawal. It is part of the PRN-001 series, which is based on tezampanel, a competitive antagonist of both α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors. These receptors are subtypes of ionotropic glutamate receptors that mediate fast excitatory synaptic transmission in the central nervous system. During alcohol withdrawal, the brain experiences a state of glutamatergic hyperexcitability; PRN-001-03 is designed to counteract this by blocking the overactivation of AMPA and kainate receptors. As of early 2024, PRN-001-03 is in the preclinical stage of development.
Beyond the preview
Go deeper on PRN-001-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRN-001-03.